Peter Schmid, MD, PhD, discusses the background, methods, and design of the phase 3 KEYNOTE-522 trial. This is a modal window. The Playback API request failed for an unknown reason Error Code: VIDEO_CLOUD_ERR_UNKNOWN Technical details : Unknown catalog request error. Session ID: 2025-...
KEYNOTE-522 (NCT03036488) is a phase III study of neoadjuvant pembro + chemo followed by adjuvant pembro vs neoadjuvant placebo + chemo followed by adjuvant placebo in pts with TNBC. Trial design: Eligible pts are aged ≥18 y with previously untreated, centrally confirmed, nonmetastatic TNBC, ...
Can you give us your thoughts on that trial, Sara? Sara A. Hurvitz, MD: Absolutely. The KEYNOTE-522 trial was the study that led to the approval of the first immune checkpoint inhibitor for breast cancer in early stage disease. In this study design, patients who had triple-negative ...
The DMC has now recommended that the trial continue without changes to evaluate the other dual primary end point of event-free survival (EFS), per the trial design. Results from the trial will be presented at an upcoming medical meeting. ...
While the exact treatment combination that was used for this patient has not been studied in a randomized controlled trial for breast cancer, we do note that chemotherapy is routinely used in combination with PD1 blockade or in combination with anti-HER2 therapy separately. Further, anti-HER2 ther...
Study Design for KEYNOTE-006 Phase 3 Trial vs Ipilimumab Evaluating OS and PFS8 Study Overview Open-label, multicenter, active controlled trial of 834 patients Select Eligibility Criteria Age ≥18 years Unresectable or metastatic melanoma ...
Martin GoreElsevier Inc.Gynecologic OncologyAnna Stevenson, Martin Gore. (2003) Specific Keynote: Clinical Trial Design Problems in Ovarian Cancer. Gynecologic Oncology 88 , S117-S121 /AnnaStevenson, MartinGore. (2003) Specific Keynote: Clinical Trial Design Problems in Ovarian Cancer. Gynecologic ...
uninstall Keynote; for this procedure to work, an application removal tool must be used, App Delete has a free trial and works for this procedure. It can be downloaded from the developer’s website here: App Delete empty the Trash (Finder > Empty Trash) restart the Mac (Apple Menu > ...
Dr. Motzer reviews the efficacy and safety data from the KEYNOTE-427 trial. EP: 1.Initial Impression of Case EP: 2.Appropriateness of Initial Therapy Now Viewing EP: 3.Efficacy and safety of KEYNOTE-427 EP: 4.Efficacy and Safety and Emerging Combinations ...